| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |